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FOCUS ISSUE: BIOMARKERSISTATE-OF-THE-ART PAPERS277BNP 10 Years After the Publication of the Breathing Not Properly StudyAlan S. Maisel, Lori B. Daniels
Since the initial studies showing the usefulness of B-type natriuretic peptide (BNP) for aiding
in heart failure diagnosis, a vast number of other clinical applications for this neurohormone
have emerged. In addition to refining our capabilities to diagnose and prognosticate in acute
heart failure, natriuretic peptides (NPs) are now being utilized in outpatient heart failure
clinics, in screening programs, and in risk prediction algorithms in various settings. In just
10 years, BNP has gone from being an unknown biomarker to being one of the most useful.
In this perspective piece, Maisel and Daniels review what we have learned about using NPs
over the past 10 years, and the advances we anticipate in the use of NPs over the next decade.STATE-OF-THE-ART PAPERS
283ntegrating Genetic Information and Protein Biomarkers
in the Diagnosis and Management of Dilated CardiomyopathySanaz Piran, Peter Liu, Ana Morales, Ray E. Hershberger
This review by Piran and colleagues provides the rationale for integrating genomic information
and protein biomarkers in the diagnosis and management of dilated cardiomyopathy (DCM).
DCM may remain asymptomatic for years. While molecular genetic testing can identify
those at risk for genetic DCM, epigenetic and sentinel phenomic staging can help to
identify those in need of intervention. Phenomic staging includes integrating clinical and
imaging features, transcriptomics, higher order proteomics and metabolomics, and
epidemiological data. By targeting patients using this information, it may be possible to
alter the natural history of DCM.(continued on page A-22)
JULY 24, 2012 (continued) A-22CLINICAL RESEARCH290Circulating MicroRNA Pattern Associated With Increased Risk of MIAnna Zampetaki, Peter Willeit, Lindsey Tilling, Ignat Drozdov, Marianna Prokopi, Jean-Marie Renard,
Agnes Mayr, Siegfried Weger, Georg Schett, Ajay Shah, Chantal M. Boulanger, Johann Willeit,
Philip J. Chowienczyk, Stefan Kiechl, Manuel Mayr
Zampetaki and colleagues explored the relationship between circulating levels of microRNAs
(miRNAs) and the subsequent risk of incident myocardial infarction (MI) over the next 10
years. Nineteen candidate miRNAs were quantified by real time polymerase chain reactions in
820 participants. In multivariable Cox regression analysis, 3 miRNAs were consistently and
significantly related with incident MI: miR-126 showed a positive association (multivariable
hazard ratio: 2.69), while miR-223 and miR-197 were inversely associated with disease risk
(multivariable HR: 0.47 and 0.56). In subjects at increased risk for subsequent MI, differential
co-expression patterns of circulating miRNAs occur around endothelial-enriched miR-126,
which seems to come from platelets.Editorial Comment: Stefan Engelhardt, p. 300CLINICAL RESEARCH304Neuronal Biomarkers May Help Predict Outcomes After OHCASharon Einav, Nechama Kaufman, Nurit Algur, Jeremy D. Kark
Protein S100B is expressed mainly in human astroglial cells and has a short half-life; thus,
constant elevation of S100B levels in the serum reflect ongoing release from damaged brain
tissue. Neuron specific enolase (NSE) is localized predominantly in neuronal cytoplasm;
serum NSE levels rise more slowly than S100B but are more specific for neuronal damage.
Einav and colleagues sought to determine the value of these serum biomarkers for predicting
outcome after out-of-hospital cardiac arrest (OHCA). Patients with a good outcome had
significantly lower S100B levels at all time points and lower NSE levels on days 1 and 3
compared with those with a poor outcome. Risk stratification after OCHA using both clinical
and biomarker data may substantially reduce the level of uncertainty in decision making.
Editorial Comment: Keith A. Comess, Kirk W. Beach, p. 312(continued on page A-23)
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315R-proADM Biomarker Useful for Predicting Response to Midodrine
in Patients With POTSFengwen Zhang, Xueying Li, Todd Ochs, Li Chen, Ying Liao, Chaoshu Tang, Hongfang Jin, Junbao Du
Zhang and colleagues studied the predictive value of the midregional fragment of pro-
adrenomedullin (MR-proADM) to identify children with postural orthostatic tachycardia
syndrome (POTS) who will respond to midodrine. Plasma levels of MR-proADM were
significantly higher in 57 children with POTS than in the control group. The plasma levels
of MR-proADM were significantly higher in responders to midodrine than nonresponders.
Using a cutoff value for MR-proADM of 61.5 pg/ml produced both high sensitivity (100%)
and specificity (71.6%). MR-proADM can identify children with POTS who will benefit
from midodrine therapy.Editorial Comment: David G. Benditt, Lin Y. Chen, p. 321CLINICAL RESEARCH
324irculating Apoptotic Endothelial Cells and Microparticles
May Signify Cardiac Allograft VasculopathyNeha Singh, Eline Van Craeyveld, Marc Tjwa, Agnieszka Ciarka, Jan Emmerechts, Walter Droogne,
Stephanie C. Gordts, Vincent Carlier, Frank Jacobs, Steffen Fieuws, Johan Vanhaecke,
Johan Van Cleemput, Bart De Geest
Singh and colleagues investigated whether biomarkers related to endothelial injury and repair
discriminate between cardiac allograft vasculopathy (CAV)-negative and CAV-positive heart
transplant recipients. Flow cytometry was used to quantify endothelial progenitor cells
(EPCs), circulating endothelial cells (CECs), and endothelial microparticles. EPC number
and EPC function did not differ between CAV-negative and CAV-positive patients. The
concentration of apoptotic endothelial microparticles and of apoptotic CECs, however, was
significantly higher. These results may be useful for the noninvasive identification of CAV.CLINICAL RESEARCH332PAPP-A Levels Predict Risk of Recurrent Thrombotic Events After NSTE-ACSMarc P. Bonaca, Benjamin M. Scirica, Marc S. Sabatine, Petr Jarolim, Sabina A. Murphy,
Janna S. Chamberlin, Daniel W. Rhodes, Paula C. Southwick, Eugene Braunwald, David A. Morrow
Pregnancy-associated plasma protein-A (PAPP-A) is a high molecular weight, zinc-binding
metalloproteinase that is associated with vulnerable plaque. Bonaca and colleagues investigated
the utility of PAPP-A for predicting risk in almost 4,000 patients presenting with non–ST-
segment elevation acute coronary syndrome (NSTE-ACS). PAPP-A 6.0 IU/ml at present-
ation was associated with higher rates of cardiovascular death or myocardial infarction at
30 days (hazard ratio [HR]: 2.01) and 1 year (HR: 1.63). The relationship with severe
recurrent ischemic events differentiates PAPP-A from other markers that reliably predict
only all-cause mortality and heart failure.(continued on page A-24)
JULY 24, 2012 (continued) A-24ECLINICAL RESEARCH339NGAL Useful for Predicting Outcomes in STEMI PatientsSøren Lindberg, Sune H. Pedersen, Rasmus Mogelvang, Jan Skov Jensen, Allan Flyvbjerg, Søren Galatius,
Nils E. Magnusson
Lindberg and colleagues investigated the prognostic role of neutrophil gelatinase-associated
lipocalin (NGAL) in a large population of patients with ST-segment elevation myocardial
infarction (STEMI). NGAL is a glycoprotein released by damaged renal tubular cells; new
data have demonstrated that NGAL is also stored in granules of mature neutrophils and
suggest a role in the development of atherosclerosis. Almost 600 consecutive STEMI patients
had blood samples drawn before primary percutaneous coronary intervention. Patients with
high NGAL (75th percentile) had increased risk of all-cause mortality and major adverse
cardiac events (MACE) compared with patients with low NGAL. High NGAL remained an
independent predictor of all-cause mortality and MACE after multivariable adjustment.CLINICAL RESEARCH
346levated Levels of Neuropeptide PENK-A Predict Mortality and
Functional Outcome After Ischemic StrokeWolfram Doehner, Stephan von Haehling, Jennifer Suhr, Andreas Schuster, Eike Nagel, Arthur Melms,
Thomas Wurster, Konstantinos Stellos, Meinrad Gawaz, Boris Bigalke
The precursor neuropeptides proenkephalin A (PENK-A) and protachykinin (PTA) are
markers of blood brain barrier integrity. Doehner and colleagues investigated the utility of
these proteins for predicting outcomes of patients presenting with symptoms of acute stroke.
PENK-A was significantly elevated in patients diagnosed with ischemic stroke compared with
patients with transient ischemic attack or nonischemic events. High concentrations of
PENK-A, but not PTA were related to severity of stroke as assessed by National Institutes of
Health Stroke Scale (NIHSS). After adjusting for age, NIHSS, and brain lesion size
(computed tomography), PENK-A predicted mortality. PENK-A appears to be a prognostic
biomarker in the acute phase of ischemic stroke.
